This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Wednesday's Early Winners & Losers

Indevus Pharmaceuticals (IDEV) surged 11.8% in after-hours trading Tuesday after announcing it would out-license the worldwide rights to its antifungal compound aminocandin to fellow pharmaceutical Novexel, a French company spun out from Sanofi-Aventis (SNY - Get Report) that, in turn, licenses the product to Indevus.

The Lexington, Mass.-based company acquired the rights to aminocandin from Aventis in 2003 before the latter merged with Sanofi. In the out-licensing deal, Indevus says it will receive $1.5 million up front, $2 million at the start of midlevel trials and $41 million in potential milestones, plus royalties on all future sales of the product. It needn't pay "significant" milestone payments or royalties to Sanofi, either. Shares were up 90 cents to $8.50.

Versant (VSNT) soared after the small software company nearly tripled its profits for the fourth fiscal quarter and swung to a fiscal full-year profit. For the quarter ended Oct. 31, the Fremont, Calif.-based company posted income of $1.4 million, or 38 cents a share, including a one-time gain of about $500,000 from the sale of its consulting business. This compares with $512,000, or 14 cents a share, a year ago. Revenue also rose 21% year over year to $4.6 million. In full-year 2006 the company earned $4.3 million, a solid improvement over its $14.6 million loss last year. Full-year revenue rose to $16.7 million from $15.7 million in fiscal 2005.
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CPRT $42.84 0.00%
PLAB $10.58 0.00%
SNY $41.10 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs